Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections

Bruce E Silverstein,1 Timothy W Morris,2 Lynne S Gearinger,2 Heleen H DeCory,2 Timothy L Comstock21Shasta Eye Medical Group Inc, Redding, CA, 2Bausch and Lomb Inc, Rochester, NY, USABackground: The purpose of this study was to determine the efficacy of besifloxacin ophthalmic suspension 0.6% when us...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Silverstein BE, Morris TW, Gearinger LS, DeCory HH, Comstock TL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/295304b480c54ffb87fae764ca57e379
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:295304b480c54ffb87fae764ca57e379
record_format	dspace
spelling	oai:doaj.org-article:295304b480c54ffb87fae764ca57e3792021-12-02T02:29:37ZBesifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections1177-54671177-5483https://doaj.org/article/295304b480c54ffb87fae764ca57e3792012-11-01T00:00:00Zhttp://www.dovepress.com/besifloxacin-ophthalmic-suspension-06-in-the-treatment-of-bacterial-co-a11645https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Bruce E Silverstein,1 Timothy W Morris,2 Lynne S Gearinger,2 Heleen H DeCory,2 Timothy L Comstock21Shasta Eye Medical Group Inc, Redding, CA, 2Bausch and Lomb Inc, Rochester, NY, USABackground: The purpose of this study was to determine the efficacy of besifloxacin ophthalmic suspension 0.6% when used in the treatment of bacterial conjunctivitis infections due to Pseudomonas aeruginosa.Methods: We undertook a post hoc analysis of clinical outcomes in patients with bacterial conjunctivitis due to P. aeruginosa across four prospective, multicenter, double-masked, randomized, controlled, clinical studies of besifloxacin ophthalmic suspension 0.6%. Efficacy outcomes included bacterial eradication and clinical resolution of the baseline infection at follow-up visits. Bacterial eradication was defined as the absence of ocular bacterial species present at or above threshold at baseline, while clinical resolution was defined as grade 0 ocular discharge and bulbar conjunctival injection. Safety outcomes included the incidence of adverse events, changes in visual acuity, and biomicroscopy and ophthalmoscopy findings. Patient outcomes were summarized and bacterial eradication and clinical resolution rates integrated.Results: Of 1317 patients with culture-confirmed bacterial conjunctivitis across four clinical studies, nine (0.7%) were infected with P. aeruginosa at baseline, and of these, five were randomized to treatment with besifloxacin ophthalmic suspension 0.6%. Bacterial eradication of the baseline infection was observed at both follow-up visits in all five patients. Clinical resolution was achieved in two of five patients by the first follow-up visit and four of five patients by the second follow-up visit. There were no adverse events reported in these patients. There were no clinically meaningful biomicroscopy findings or changes in ophthalmoscopy or visual acuity.Conclusion: The incidence of bacterial conjunctivitis due to P. aeruginosa was low. Treatment of patients with P. aeruginosa infections with besifloxacin ophthalmic suspension 0.6% led to bacterial eradication of P. aeruginosa by the first follow-up visit and high rates of clinical resolution.Keywords: bacterial conjunctivitis, besifloxacin ophthalmic suspension, besifloxacin, conjunctivitis, Pseudomonas aeruginosaSilverstein BEMorris TWGearinger LSDeCory HHComstock TLDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 1987-1996 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Silverstein BE Morris TW Gearinger LS DeCory HH Comstock TL Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
description	Bruce E Silverstein,1 Timothy W Morris,2 Lynne S Gearinger,2 Heleen H DeCory,2 Timothy L Comstock21Shasta Eye Medical Group Inc, Redding, CA, 2Bausch and Lomb Inc, Rochester, NY, USABackground: The purpose of this study was to determine the efficacy of besifloxacin ophthalmic suspension 0.6% when used in the treatment of bacterial conjunctivitis infections due to Pseudomonas aeruginosa.Methods: We undertook a post hoc analysis of clinical outcomes in patients with bacterial conjunctivitis due to P. aeruginosa across four prospective, multicenter, double-masked, randomized, controlled, clinical studies of besifloxacin ophthalmic suspension 0.6%. Efficacy outcomes included bacterial eradication and clinical resolution of the baseline infection at follow-up visits. Bacterial eradication was defined as the absence of ocular bacterial species present at or above threshold at baseline, while clinical resolution was defined as grade 0 ocular discharge and bulbar conjunctival injection. Safety outcomes included the incidence of adverse events, changes in visual acuity, and biomicroscopy and ophthalmoscopy findings. Patient outcomes were summarized and bacterial eradication and clinical resolution rates integrated.Results: Of 1317 patients with culture-confirmed bacterial conjunctivitis across four clinical studies, nine (0.7%) were infected with P. aeruginosa at baseline, and of these, five were randomized to treatment with besifloxacin ophthalmic suspension 0.6%. Bacterial eradication of the baseline infection was observed at both follow-up visits in all five patients. Clinical resolution was achieved in two of five patients by the first follow-up visit and four of five patients by the second follow-up visit. There were no adverse events reported in these patients. There were no clinically meaningful biomicroscopy findings or changes in ophthalmoscopy or visual acuity.Conclusion: The incidence of bacterial conjunctivitis due to P. aeruginosa was low. Treatment of patients with P. aeruginosa infections with besifloxacin ophthalmic suspension 0.6% led to bacterial eradication of P. aeruginosa by the first follow-up visit and high rates of clinical resolution.Keywords: bacterial conjunctivitis, besifloxacin ophthalmic suspension, besifloxacin, conjunctivitis, Pseudomonas aeruginosa
format	article
author	Silverstein BE Morris TW Gearinger LS DeCory HH Comstock TL
author_facet	Silverstein BE Morris TW Gearinger LS DeCory HH Comstock TL
author_sort	Silverstein BE
title	Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
title_short	Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
title_full	Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
title_fullStr	Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
title_full_unstemmed	Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
title_sort	besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with pseudomonas aeruginosa infections
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/295304b480c54ffb87fae764ca57e379
work_keys_str_mv	AT silversteinbe besifloxacinophthalmicsuspension06inthetreatmentofbacterialconjunctivitispatientswithpseudomonasaeruginosainfections AT morristw besifloxacinophthalmicsuspension06inthetreatmentofbacterialconjunctivitispatientswithpseudomonasaeruginosainfections AT gearingerls besifloxacinophthalmicsuspension06inthetreatmentofbacterialconjunctivitispatientswithpseudomonasaeruginosainfections AT decoryhh besifloxacinophthalmicsuspension06inthetreatmentofbacterialconjunctivitispatientswithpseudomonasaeruginosainfections AT comstocktl besifloxacinophthalmicsuspension06inthetreatmentofbacterialconjunctivitispatientswithpseudomonasaeruginosainfections
_version_	1718402455620812800

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections

Ejemplares similares